Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study

Nephrology
Rebecca S Ahdoot
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Kidney - Nephrology

Study Description

Eligibility

  1. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Class 1C, 1D, or 1E based on the Mayo Clinic Imaging Classification of ADPKD.
  2. Estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m^2 and less than 90 mL/min/1.73 m^2, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at Screening.
  1. Current interventions to treat ADPKD such as non-approved medications or lifestyle modifications.
  2. Any exclusionary medical diseases, disorders, or conditions as described in the protocol.
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.